PD-L1: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
[[Category:Cancer]] | [[Category:Cancer]] | ||
[[Category:Therapeutic targets]] | [[Category:Therapeutic targets]] | ||
<gallery> | |||
File:B7_family_ligands_and_CD28_family_receptors.JPG|B7 family ligands and CD28 family receptors | |||
File:PD-L1_positive_lung_adenocarcinoma_--_high_mag.jpg|PD-L1 positive lung adenocarcinoma -- high magnification | |||
</gallery> | |||
Latest revision as of 01:58, 18 February 2025
PD-L1 or Programmed Death-Ligand 1 is a type of protein that is found on the surface of some cells in the body. It plays a significant role in suppressing the immune system during particular events such as pregnancy, autoimmune disease, and other disease states such as hepatitis.
Function[edit]
PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition. High expression of PD-L1 in cancer can protect the cancer cells from cytotoxic T cell activity.
Role in Cancer[edit]
In many cancers, the PD-L1 protein is overexpressed. This overexpression can be caused by either genetic changes in the cancer cells or by factors in the cancer's microenvironment. When PD-L1 binds to PD-1, it sends a signal that inhibits the T-cell's function, including its ability to kill cancer cells. This is one way that cancers evade the immune system.
Therapeutic Target[edit]
PD-L1 has been identified as a potential therapeutic target in cancer treatment. Drugs that block the interaction between PD-1 and PD-L1 can boost the immune response against cancer cells. These drugs, known as PD-1/PD-L1 inhibitors, have shown promise in the treatment of a variety of cancers.
See Also[edit]
References[edit]
<references />


